Norbert Riedel

Insider profile

Currently holds positions in Oscient Pharmaceuticals Corp, Jazz Pharmaceuticals PLC and Aptinyx Inc

Performance

Overall performance
3.4
Performance over holding periods
3.4
30 days 90 days 120 days
Average return 3% 8.2% 15.1%
Success rate 92% 68% 82%
Transactions
8 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director Oscient Pharmaceuticals Corp Jan. 1, 1999 -
Independent Director Jazz Pharmaceuticals PLC May 2, 2013 -
President, Chief Executive Officer, Director Aptinyx Inc June 1, 2015 -
Independent Director ARIAD Pharmaceuticals Inc April 28, 2011 - Feb. 16, 2017
Deputy Chairman of the Supervisory Board Medigene AG Oct. 27, 2003 - July 16, 2013
Corporate Vice President, Chief Scientific Officer Baxter International Inc. May 1, 2001 - Jan. 1, 2012
Norbert Riedel's trades of Jazz Pharmaceuticals PLC's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
325.49
Quantity 69,975
Value US$4,095,339
Transaction date
Sale
Price
351.32
Quantity 91,379 +45.5%
Value US$2,330,372
Transaction date
Proposed sale
Price
147.29
Quantity 51,809
Value US$3,821,211
Transaction date
Proposed sale
Price
112.00
Quantity 3,731
Value US$417,872
Transaction date
Proposed sale
Price
111.00
Quantity 3,075
Value US$341,325
Transaction date
Proposed sale
Price
135.18
Quantity 2,561
Value US$346,196
US Aptinyx Inc (APTX)
Transaction date
Purchase
Price
2.23
Quantity 100,000 New position
Value US$223,000
US Aptinyx Inc (APTX)
Transaction date
Purchase
Price
3.00
Quantity 35,000 New position
Value US$105,000
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-31 2026-08-31
PrS Proposed sale
69,975
325.49
US$4,095,339 		69,975 325.49 US$4,095,339
2026-03-02 2026-02-27
S Sale
91,379 +45.5%
351.32
US$2,330,372 		91,379 +45.5% 351.32 US$2,330,372
2026-02-27 2026-02-27
PrS Proposed sale
51,809
147.29
US$3,821,211 		51,809 147.29 US$3,821,211
2025-08-08 2025-08-08
PrS Proposed sale
3,731
112.00
US$417,872 		3,731 112.00 US$417,872
2024-08-05 2024-08-06
PrS Proposed sale
3,075
111.00
US$341,325 		3,075 111.00 US$341,325
2023-08-15 2023-08-14
S Sale
1,241 -8.3%
138.16
US$171,454 		1,241 -8.3% 138.16 US$171,454
2023-08-14 2023-08-14
PrS Proposed sale
2,561
135.18
US$346,196 		2,561 135.18 US$346,196
2022-08-09 2022-08-08
S Sale
1,089 -8.4%
152.32
US$165,877 		1,089 -8.4% 152.32 US$165,877
2022-08-09 2022-08-05
S Sale
8,000 -43.5%
155.87
US$1,246,920 		8,000 -43.5% 155.87 US$1,246,920
2021-12-08 2021-12-06
US Aptinyx Inc (APTX)
B Purchase
100,000 New position
2.23
US$223,000 		100,000 New position 2.23 US$223,000
2020-08-10 2020-08-07
S Sale
931 -9.0%
125.87
US$117,186 		931 -9.0% 125.87 US$117,186
2020-01-14 2020-01-10
US Aptinyx Inc (APTX)
B Purchase
35,000 New position
3.00
US$105,000 		35,000 New position 3.00 US$105,000
2018-08-13 2018-08-10
S Sale
660 -9.2%
176.61
US$116,563 		660 -9.2% 176.61 US$116,563
2016-08-17 2016-08-15
S Sale
633 -11.3%
136.45
US$86,373 		633 -11.3% 136.45 US$86,373
2016-05-17 2016-05-16
S Sale
644 -13.2%
145.20
US$93,509 		644 -13.2% 145.20 US$93,509